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Summary It has been suggested that the percentage of non-protein-bound or free oestradiol (E2) is abnor-
mally high in patients with breast cancer. In this study, the serum oestradiol profiles of a large group of
women were analysed to determine whether a significant correlation could be found between serum oestradiol
and various breast diseases. In addition oestradiol levels were measured in relation to sex hormone binding
globulin (SHBG), albumin levels, oestrogen receptor status and family history of breast cancer. Serum samples
were taken from a total of 300 women who had either no breast disease, benign breast disease or breast
cancer. The percentage of free oestradiol was found to be highest in women with breast cancer, lowest in the
control group and intermediate for the women with benign breast disease. These differences were most marked
in post-menopausal women. The absolute values for total and free oestradiol were not statistically different in
the three groups studied. There did not appear to be a correlation between oestrogen receptor (ER)
concentration in breast cancer tissue and free E2 percentage levels. Women who had a family history of breast
cancer did not appear to have higher percentage levels of free E2 than those with no such history. The presence
of elevated proportions of free oestradiol in the serum of women with breast cancer may be significant in
regard to understanding the aetiology of breast neoplasia. There also may be important implications for the
use of this measurement in the earlier diagnosis and detection of breast cancer.
Endogenous hormones, in particular oestrogens, have long
been recognised as having a fundamental role in the develop-
ment and progress of breast cancer. As early as 1835 Sir
Astley Cooper made the observation that nulliparous women
were more likely to develop breast cancer, and in 1896
George Beatson in Glasgow demonstrated that oophorec-
tomy could induce remission of advanced breast cancer in
premenopausal patients.
In more recent times a role for oestrogens in the aetiology
of breast cancer has been suggested by numerous laboratory,
epidemiological and clinical studies (Kelsey & Hildreth,
1983). Animal studies have demonstrated that oestrogens can
induce and promote mammary tumours in rodent.
Epidemiological evidence concerning this role includes the
rarity of the disease in males, the increased risk associated
with nulliparity, a late age at first live birth, an early age of
menarche and a late age at menopause, and a decreased risk
following oophorectomy. Endocrine ablation therapy includ-
ing oophorectomy, adrenalectomy, hypophysectomy and
administration of anti-oestrogens may lead to regression of
breast cancer. However, the underlying biological relation-
ship between breast cancers and oestrogens still remains
poorly understood.
Lately attention has focused on one of the forms of oest-
rogen, oestradiol, which exists in the serum in both a bound
form (bound to either SHBG or albumin) and in an unbound
from which is the biologically active component. Studies have
recently suggested that serum oestradiol levels, and partic-
ularly the percentage of free oestradiol, may be higher in
breast cancer patients than in matched controls (Siiteri et al.,
1981; Moore et al., 1982; Reed et al., 1983; Ota et al., 1986).
This work suggested that the greater availability of free
oestradiol may provide a stimulus to breast cancer develop-
ment. The original work by Moore et al. (1982) has received
some support from other centres. The explanation for the
elevation in the free oestradiol fraction remains unclear.
We have examined the serum oestradiol profiles of a group
of 300 women in order to assess the relationship between
oestradiol levels and breast disease. In addition to comparing
both a control group and a group of women with breast
cancer, we have also studied a subset of 117 women with
proven benign breast disease. This is one of the largest study
groups so far reported of women with proven benign breast
disease in whom the serum oestradiol profiles has been
analysed.
Total serum oestradiol, free oestradiol concentration and
the free oestradiol percentage have been measured in all
patients. The relationship between free oestradiol percentage
and breast disease, SHBG and albumin levels, oestrogen
receptor status and family history of breast cancer has been
evaluated.
Subjects and methods
Subjects
Blood was collected by venepuncture from a total of 300
women who attended either a breast screening clinic at the
Royal Women's Hospital or were to have an operation at the
Royal Brisbane Hospital. On the basis of clinical findings,
mammography and histology where relevant, three categories
were established, a control group, patients with benign breast
disease and patients with breast cancer.
The control group consisted of asymptomatic, well women
attending the Royal Women's Hospital breast screening clinic
who were found to have no breast disease at all, having a
normal clinical examination and normal mammogram.
The benign breast disease group was made up of: (i)
women with clinical or mammographic evidence of benign
disease; or (ii) women who had a biopsy with the histological
diagnosis of benign disease.
Patients with breast cancer were those having operative
procedures undertaken with positive histological evidence of
the malignancy. In some cases this was confined to a trucut
biopsy in patients being treated by methods other than sur-
gical. The oestrogen receptor (ER) values for all the tumours
was also recorded.
Information was collected from the patients concerning
menopausal status, family history of breast cancer, thyroid
function, and medication regimens (including the use of oral
contraceptives and hormone replacement therapy). Height
and weight were recorded, and a Quetelet index (kgm-2)
was calculated for each patient. Each cancer patient was
matched for weight and age with a control patient and a
patient with benign breast disease.
In premenopausal patients, blood samples were not taken
at any predetermined time in the menstrual cycle as our
previous work had shown that the percentage of oestradiol
was not significantly altered during the cycle.
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Methods ofblood sampling
Twenty ml of blood were taken from each individual and
collected in sterile clotting tubes. Serum was separated by
centrifugation and stored at - 20°C before analysis. Patients
undergoing breast biopsy or surgical treatment for proven
breast cancer had samples taken before the operative proce-
dure.
Analytical methods
The percentage of free oestradiol was determined using a
centrifugal ultrafiltration dialysis technique (Moore et al.,
1987). The reagents used in the experimental protocol were
D-U-'4C-glucose (250 mCi mmol-') and 6,7-3H-oestradiol
(48.2 Ci mmol '), which were obtained from New England
Corporation (Boston, MA, USA). Working solutions of the
labels were prepared immediately before use.
Undiluted serum (450 gil) was incubated with
3 x 105d.p.m. 3H-oestradiol-17-P and 12 x I03d.p.m. 14C-
glucose for 30 min at 37°C and at room temperature for a
further 30 min. Separation of the free and protein-bound
ligand was achieved using the AMICON MPS-1 centifree
micropartition system. Aliquots (200 gil) of the reaction mix-
ture were transferred to duplicate MPS-1 devices and cent-
rifuged at 2,000 g for 30 min at 37°C. The ultrafiltrate (non-
protein-bound fraction) was retained and the retentate
(protein-bound fraction) obtained on washing of the
ultrafiltration membrane with distilled water and recent-
rifugation. Both the ultrafiltrate and retentate were taken up
in a Pico-flor-15 liquid scintillation spectrophotometer
adjusted for simultaneous measurement of 3H and '4C. The
ratio of 3H-oestradiol and '4C-glucose in the ultrafiltrate and
retentate was used to calculate the percentage of non-protein-
bound oestradiol (% free E2) using the following formula:
% free E2 =
3H-E2 c.p.m. 3H-E2 c.p.m. x 100
Ultrafiltrate '4C-glucose Retentate 14C-glucose
c.p.m. c.p.m.
Inter-assay and intra-assay co-efficients of variance using this
procedure were 9.8% and 8.3% respectively.
Total oestradiol concentration was measured by conven-
tional radioimmunassay. The free oestradiol concentration
was then calculated from the derived values of total oest-
radiol and free oestradiol.
The two proteins important in binding oestradiol are sex
hormone binding globulin (SHBG), because of its high
affinity, and albumin, because of the large amount available.
The concentrations of these proteins were measured to see
whether variations in one or both could account for the
differences in free oestradiol percentage. SHBG levels were
determined using a radioimmunoassay technique (Anderson,
1974). Serum albumin was measured using bromo-cresol-
green dye and automated colour metric analyser (Pinnel et
al., 1978).
Statistics
Data have been expressed in terms of the mean ± standard
deviation. The significance of differences between mean
values was determined using the Student's t test. A pro-
bability of P<0.05 was regarded as statistically significant.
Correlation between assays was tested using bio-regression
analysis using the method of least squares.
Results
Patient characteristics
A total of 300 women were included in the study: 143 women
in the control group, 117 women with benign breast disease
and 40 women with breast cancer. Of these, 110 women were
premenopausal and 190 were post-menopausal. In the group
with cancer, eight were premenopausal and 32 were post-
menopausal.
Age, height, weight and Quetelet index for each group are
shown in Table I. Women with malignancy were of a slightly
older age group. They also had a higher mean weight, but
when height was also taken into account and the Quetelet
index estimated, the three groups were evenly matched.
The number of patients on the contraceptive pill or on
hormonal replacement therapy was low and numbers were
even through the three groups. Only a few patients had a
past history of thyroid disease and all had adequate hormone
replacement.
Percentagefree oestradiol
Total population In the study population the mean free
oestradiol percentage was 1.70 with a standard deviation of
0.4. Within the breast cancer group, the mean free oestradiol
percentage was 1.98 (± 0.5) which was significantly higher
than the control group 1.60 (± 0.4) (P<0.001) and women
with benign breast disease 1.72 (± 0.4) (P<0.01) (see Table
II). These same trends persisted when the control and benign
patients were weight and age matched with cancer patients
(Table III). An important finding is that 67% of breast
cancer patients had a percentage free E2 level greater than the
mean value of 1.70. The frequency ofpatients with malignant
disease having percentage free E2 values greater than that for
normal women (X2 = 13.54, 5 d.f., 0.05>P>0.01).
Further subdivision of the benign breast disease group was
done into those with clinical and/or mammographic evidence
of benign disease and those with benign disease requiring
surgical biopsy because of a concern about the possibility of
malignancy. It was found that the biopsy group had a higher
level of free oestradiol percentage than the former (Table IV).
Thus there is an incremental trend present in progressing
from the control group to the biopsy benign group to the
carcinoma group.
Menopausal status When menopausal status was taken into
account (Table V), the same trend of increasing free
oestradiol percentage from control to benign malignant is
observed. The difference was significant in the
post-menopausal group (P<0.001), and was clearly present
but not as statistically strong (P = 0.056) in the
premenopausal cancer patients. The mean free oestradiol
percentage in premenopausal women was 1.73 (± 0.4), not
significantly different from that of post-menopausal women,
1.68 (± 0.4) (P<0.36).
Weight There was no significant correlation between free
E2% and weight (r value = - 0.015). Although patients in
the malignancy group tended to have higher weights, the
higher values of free E2% in this group were not related to
this.
ER status There was no significant relationship between the
oestrogen receptor value (fmolmg-' protein) and free
oestradiol percentage (r = -0.142).
Concentrations oftotal andfree oestradiol
There was no significant difference in the absolute values of
free E2 or total E2 in patients with breast cancer when
compared with either the control group or women with
benign breast disease (Tables II and III).
Even when the groups are subdivided into premenopausal
and post-menopausal, no clear trend could be noted between
the control, benign and malignant groups for either free
oestradiol or total oestradiol (Table V).
Premenopausal women have higher values for both mean
free oestradiol concentration and total oestradiol concentra-
tion than do post-menopausal women (P<0.0001 both
groups).144 I.C. BENNETT et al.
Table I Characteristics of total population grouped according to disease status
Parameter Control Benign Malignant
No. of patients 143 117 40
Age (years, mean ± s.d.) 62.77 ± 11.18 61.73 ± 10.48 68.16 ± 11.95
Weight (kg, mean ± s.d.) 53.53 11.65 51.08 10.61 62.00 13.71
Mean QI 23.84 23.48 22.45
(kgm-2) (range) (17.53-40.79) (19.66-28.58) (18.56-24.56)
Contraceptive pill 5 3 2
HR therapy 7 6 1
Thyroid disease 11 5 2
Table II Total, free and percentage free oestradiol values versus breast disease status for
total population
Breast disease status
Control Benign Malignant
Parameter (n = 143) (n = 117) (n = 40)
Total E2 (pmol 1) 181 316 246 327 117 212
log10 Total E2 1.96 ± 0.4 2.03 ± 0.5 1.85 ± 0.4
(C) free E2 (pmol ) 3.2 ± 6.5 4.5 ± 6.3 2.5 ±4.4
log10 (C) free E2 0.08 ± 0.3 0.25 ± 0.5 0.16 ± 0.4
%free E2 1.60±0.4 1.72±0.4 1.98±0.5
The % free E2 recorded for women with malignant disease is significantly higher than
that recorded for normal controls (P<0.001) and benign disease (P<0.01).
Table III Oestradiol values versus breast disease status with control and benign disease
patients matched weight and age for each cancer patient
Breast disease status
Control Benign Malignant
Parameter (n = 40) (n = 40) (n = 40)
Log10 total E2 1.74 ± 0.3 1.88 ± 0.4 1.85 ±0.4
Log10 (C) free E2 0.07 ± 0.3 0.07 ± 0.4 0.16 ± 0.4a
%free E2 1.58±0.3 1.60±0.4 1.980.5b,c
Serum oestradiol levels for normal controls and patients with benign breast disease
matched for weight and age with each cancer patient. The free oestradiol and total
oestradiol levels are expressed as log10 values. Significance levels where appropriate are
indicated on the table by the following symbols. aMalignant disease significantly greater
than normal controls P<0.01. bMalignant disease significantly greater than normal
controls P<0.001. cMalignant disease significantly greater than benign disease P<0.001.
Table IV Percentage free E2 versus breast disease status
Clinically Biopsy
Control benign benign Malignant
(n = 143) (n= 96) (n =21) (n =40)
Free E2% 1.60 ± 0.4 1.70 ± 0.4 1.82 ± 0.4 1.98 ± 0.5
The % freeoestradiol levels forwomen classified according to breastdisease status. The
value recorded forwomen with malignant breast disease was significantly higherthan that
recorded for normal controls and patients with clinically benign disease (P<0.001), but
not for biopsy benign patients. Similarly, biopsy benign patients had significantly higher
% free oestradiol levels than normal controls (P<0.05) but not patients with clinically
benign disease.
Table V Oestradiol levels versus breast disease status in premenopausal and
post-menopausal population
Breast disease status
Control Benign Malignant
Parameter (n = 143) (n = 117) (n = 40)
Premenopausal
Total E2 (pmol 1l') 395 ± 455 338 ± 356 329 ± 371
log1o total E2 2.3 ± 0.5 2.4 ± 0.4 2.3 ± 0.4
(C) free E2 7.33 ± 9.5 6.08 ± 7.1 6.89 ± 7.01
% freeE2 1.65±0.3 1.75±0.4 2.01±0.5
(P = 0.056)
Post-menopausal
Total E2 (pmol1h') 77 110 160 ± 257 64 ± 53
log10total E2 1.8±0.7 1.8±0.4 1.7±0.2
(C) free E2 (pmol 1-') 0.02 ± 0.4 0.07 ± 0.4 1.20 ± 1.1
log10 (C) free E2 0.02 ± 0.4 0.07 ± 0.4 0.01 ± 0.3
% freeE2 1.58±0.4 1.69±0.4 1.97±0.5
(P<0.001)
The % free E2 levels in post-menopausal women with malignant disease were
significantly higher than those for normal controls and patients with benign disease
(P<0.001). There were no other differences of statistical significance.SERUM OESTRADIOL AND BREAST DISEASE 145
Binding proteins
There was no significant difference in either the albumin or
SHBG levels between the three groups (Table VI). Therefore,
the difference observed in the free oestradiol percentage
between these groups is not related to variations in the levels
of binding proteins. There is no clear relationship between
free E2% levels and either SHBG or albumin concentration.
There was no difference in the albumin and SHBG levels
noted between premenopausal and post-menopausal women.
Family history
No link could be established between family history of breast
cancer and either free E2 percentage, free E2 concentration, or
total E2 concentration (Table VII).
Discussion
Although cumulative evidence appears to support the con-
cept that endogenous oestrogens play a part in the genesis
and course of breast cancer, their exact role in this setting
remains a mystery. Endocrinological studies based on total
levels of oestrogens in the serum or urine have provided
some clues (Lemon et al., 1966; Thomas, 1986), but have
failed to yield a clear understanding of the hormonal aberra-
tions which might contribute to the development of breast
cancer. One reason for this is probably that neither urinary
hormones nor total levels of serum hormones accurately
reflect the biologically active levels to which the tissues are
exposed. Instead it would appear that levels of the free
hormone, unbound to either SHBG or albumin, may be of
more relevance, and warrant further scrutinisation. The work
by Moore et al. (1982) and others (Siiteri et al., 1981; Reed et
al., 1983; Bruning et al., 1985; Ota et al., 1986) more recently
has been innovative in the sense of looking at the complete
profile of the oestradiol distribution in sera, and particularly
in studying the free active component of the hormone. The
results of these studies suggest that women with breast cancer
have higher values of free oestradiol percentage compared to
their normal counterparts. These same reports have also
variably indicated that the levels of total oestradiol concent-
ration and free oestradiol concentration may be higher in
breast cancer patients. One recent report, however, has failed
to uphold this associatiorn between serum E2 and breast
cancer (Ernster et al., 1987).
Our study indicates that pre- and post-menopausal women
with breast cancer have higher levels of free oestradiol
percentage compared to both the control group and women
with benign breast disease. However, we did not demonstrate
any elevation of the total oestradiol or the absolute free
Table VI Binding protein concentrations compared to breast disease
status
Control Benign Malignant
(n = 143) (n = 117) (n = 40)
SHBG 58.3 ± 37 54.9 ± 28 51.9 ± 25
(mmol 1-')
Albumin 41.5 ± 2.0 41.9 ± 3.9 40.2 ± 3.1
There were no significant differences between the disease groups for
both SHBG and albumin.
Table VII Oestradiol levels versus family history of breast cancer
Family history Nofamily history
(n= 3) (n= 233)
% free E2 1.65 ± 0.25 1.67 ± 0.36
(C) free E2 (pmol 1-') 0.15 ± 0.23 0.26 ± 0.46
Total E2 (pmol1-h') 1.94± 0.40 2.05± 0.11
There were no significant differences between the two groups for any
of the parameters.
oestradiol concentrations in the malignancy group compared
to the controls in either premenopausal or post-menopausal
women. In this report, specific attention was paid to includ-
ing in the control group only those women who were shown
to be free of breast disease both clinically and mammo-
graphically. Other reports have done similarly (Moore et al.,
1982; Ota et al., 1986). In the study by Ernster et al. (1987),
however, control women were selected on the basis of a
negative past history only, without clinical or radiographic
verification of their true breast disease status, leaving the
exact nature of their control group in some doubt.
Our study is significant in being one of the firs to analyse
critically oestradiol levels in a large group of women with
proven benign breast disease (117 patients). The interesting
trend that our results show is that the benign group have free
oestradiol percentages (1.72) intermediate between the cont-
rols (1.60) and the malignant group (1.98). Even when
broken down into premenopausal and post-menopausal
groups, this trend of an increasing proportion of free oest-
radiol going from control to benign to malignant persists.
Additionally, when the benign breast disease group is further
subdivided into those with clinical or mammographic
evidence of benign disease versus those with benign disease
warranting a biopsy (and therefore presumably with more
advanced disease), the values of free oestradiol percentage
were higher in the latter group, thus maintaining this same
trend.
The difference in the free oestradiol percentage between the
three main disease categories in our study cannot be attribu-
tion to differences in the binding protein levels, as the
albumin and SHBG levels are evenly matched through the
groups. We could not demonstrate any direct relationship
between free oestradiol percentages and SHBG or albumin
levels, and this contrasts with the findings of Moore et al.
(1982) and Bruning (1985), who showed an inverse relation-
ship between SHBG levels and the free E2%, such that higher
values of free E2% were associated with lower SHBG levels
and vice versa. Langley et al. (1984) and Ota et al. (1986)
looked at the distribution of the protein-bound' oestradiol
and calculated the percentage of oestradiol specifically bound
to albumin, and they were able to demonstrate an actual shift
in the distribution of the protein-bound oestradiol from
SHBG to albumin in breast cancer patients. On the basis of
the claim by Pardridge (1984) that albumin bound steroids
tend to dissociate more rapidly, they put forward the pro-
posal that with a greater proportion of oestradiol bound
weakly to albumin in breast cancer patients, this oestradiol
may be more prone to dissociate into the free form, and thus
be more available to tissues.
Because it is the free oestradiol which is considered
biologically potent, the hypothesis which has been put for-
ward is that over-exposure of breast tissues to non-protein-
bound oestradiol may promote breast cancer development
(Anderson, 1974; Ota et al., 1986), anid in the light of our
findings might play a role in the aetiology of the broad
spectrum of benign breast disease. There is good in vitro
evidence demonstrating that human breast cancer cell culture
lines (MCF-7) proliferate much more rapidly when their
growth is stimulated by the addition of oestradiol (Lyk-
kesfeldt et al., 1986).
Alternatively, the abnormal oestradiol profile could result
from the breast cancer itself producing oestradiol. It is well
known from in vitro tissue culture studies (Santer et al., 1986;
Hawkins et al., 1985) that within breast cancer cells oest-
radiol is synthesised via the oestrone sulphatase pathway,
and in such proportions that the concentrations of oestradiol
in tumour tissues may be several-fold higher than normal
plasma levels.
Our results did not demonstrated any relationship between
percentage free oestradiol and oestrogen receptor levels in
breast cancers. We also found no correlation between family
history of breast cancer oestradiol levels in this study. Both
these findings are consistent with the reports of others (Ota et
al., 1986).
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percentage can be used as a tumour marker to aid early
breast cancer detection, and therefore whether it might play a
role in breast screening. Our data would suggest that it does
have moderate sensitivity. We found that 67% of breast
cancer patients had free E2% values greater than the mean
1.7% and the x2 test also showed it to be a significant
discriminator between the malignant and control groups. It
would certainly follow that in the clinical setting women with
high values warrant thorough assessment and work-up.
Additionally, greater sensitivity in predicting high risk
patients may be able to be achieved by using the oestradiol
estimation in combination with other classicals endo-
crinological and radiological factors. Using this combinations
of variables it has been suggested that a subset of women
may be identified with a 4-fold risk of breast cancer (Bulb-
rook et al., 1986). Estimation of free oestradiol percentage is
relatively inexpensive and can be easily performed using the
technique described. We feel it may come to have an applica-
tion in assisting early breast cancer diagnosis.
In conclusion, the present study demonstrated that women
with breast cancer had higher values of free oestradiol
percentage than both normal women and women with benign
breast disease. Additionally, women with benign disease had
greater values of free oestradiol percentage than their normal
counterparts, so that there appeared to be a distinct trend of
increasing free oestradiol percentage in progressing from nor-
mal to benign to malignant groups. These data provide
further support to the concept that breast neoplasia is
associated with an abnormal proportion of serum free oest-
radiol. While its exact role in breast cancer has not yet been
completely elucidated, we suggest that the serum free oest-
radiol percentage has potential as a useful diagnostic aid in
the assessment of women with breast disease.
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